Towa Pharmaceutical Co., Ltd.

4553

JP3623150004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,773 ^JPY	-0.11%		+0.84%	+17.90%

Mar. 25	Towa Pharmaceutical Completes Payment for Director Stock Compensation	MT
Mar. 07	VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	CI

Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016.

January 18, 2016

Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016. These shares will be under lockup for 180 days starting from 23-JUL-2015 to 19-JAN-2016.

Latest news about Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Completes Payment for Director Stock Compensation	Mar. 25	MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	Mar. 06	CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG).	22-03-06	CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion.	21-12-16	CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd.	21-03-23	CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug	21-02-18	MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan	21-02-17	CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.	20-01-30	CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors	19-12-24	CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.	19-12-22	CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation	19-11-08	CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018	16-05-13	CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016	16-02-07	CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016.	16-01-18	CI
Tranche Update on Towa Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 7, 2015.	15-09-10	CI
Towa Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 7, 2015, has expired with repurchase of 592,000 shares, representing 3.48% for ¥4,999.53 million.	15-09-09	CI
Towa Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	15-07-06	CI
Towa Pharmaceutical Co., Ltd. announces an Equity Buyback for 700,000 shares, representing 4.12% for ¥5,000 million.	15-07-06	CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2015; Provides Earnings Guidance for the Full Year Ending March 2015	14-11-09	CI
Towa Pharmaceutical Co. Ltd. Reports Earnings Results for the Third Quarter of the Year Ending March 2014; Revised Earnings Guidance for Year Ending March, 2014	14-02-09	CI
Towa Pharmaceutical Co. Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2012; Provides Earnings Guidance for the Second Quarter of Fiscal 2013	12-08-09	CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 2012; Revised Earnings Guidance for the Year Ending March 2013	12-05-13	CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Third Quarter of 2011; Reaffirms Earnings Guidance for the Year Ending March, 2012	12-02-12	CI

Chart Towa Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Towa Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,773 JPY

Average target price

3,690 JPY

Spread / Average Target

+33.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TOWA PHARMACEUTICAL CO., LTD.	+17.90%	867M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Towa Pharmaceutical Co., Ltd.

Equities

4553

JP3623150004

Pharmaceuticals

Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016.

EPS Revisions